ADIL

AdialF

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3

B+

Bull case

25%

Probability

Target price

$2.60

+6.1% vs current

Most likely

Base case

45%

Probability

Target price

$1.00

-59.2% vs current

B-

Bear case

30%

Probability

Target price

$0.35

-85.7% vs current

AI sentiment snapshot

Latest data as of 2026-05-15

AI commentary

This was a scheduled T+3 post-earnings follow-up. Primary company sourcing was confirmed through the May 11, 2026 8-K and attached earnings release plus the May 8, 2026 10-Q. The earnings read-through is mixed: Q1 burn was manageable and net loss narrowed, but the financing runway is still short and the filing retains substantial-doubt language. No trustworthy delayed analyst revision set was confirmed from checked sources, and a clean post-release price-reaction attribution was not confirmed from checked primary/trusted sources, so confidence stays capped and the thesis remains a cautious monitoring view rather than a stronger upgrade.

RankAlpha Sentiment Codex - 2026-05-15

Open post-earnings memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-09-30catalystQ1 update preserved only a short runway and keeps financing risk front and centerHigh impact

The May 11 earnings update said cash and cash equivalents were $4.6 million at March 31, 2026 and that cash would fund operating expenses only into the second half of 2026, while the 10-Q also says existing cash is not sufficient to fund the next twelve months and raises substantial doubt about continuing as a going concern; that keeps financing, dilution, or a strategic capital solution as the clearest near-term stock driver [#8-K-2026-05-11] [#10-Q-2026-05-08].

2026-12-31eventAD04 Phase 3 pathway clarification remains the main operating upside triggerHigh impact

Management said recent FDA policy discussions could support a more flexible evidentiary path and the 10-Q states it is possible Adial may conduct only one additional Phase 3 trial of AD04 depending on regulatory discussions and final trial design. If that path is clarified, capital needs and timeline assumptions could improve materially, but the outcome is still not confirmed [#8-K-2026-05-11] [#10-Q-2026-05-08].

2026-12-31catalystMolteni framework and IP progress are real optionality but still non-bindingHigh impact

The company reiterated a collaboration framework with Molteni Farmaceutici for a proposed exclusive European partnership for AD04 and highlighted patent progress that could extend AD04 protection through at least 2045 if granted. That can help the strategic narrative, but the partnership still depends on a definitive agreement and does not yet remove funding pressure [#8-K-2026-05-11] [#10-Q-2026-05-08].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-15 • Updated nightlySource: Internal modelMethodology